21 USC 1702 - Office of National Drug Control Policy

1 So in original. Probably should be “agencies’ ”.

programs, by developing and applying specific goals and performance measurements and monitoring the agencies’ program-level spending;

Editorial Notes

References in Text

This chapter, referred to in subsec. (d)(4), was in the original a reference to “this title”, meaning title VII of Puspan. L. 105–277, div. C, Oct. 21, 1998, 112 Stat. 2681–670, which is classified principally to this chapter. For complete classification of title VII to the Code, see Short Title note set out under section 1701 of this title and Tables.

Amendments

2019—Subsec. (a)(1). Puspan. L. 116–74, § 2(a)(2), substituted “National Drug Control Program agencies” for “National Drug Control Program Agencies”.

Subsec. (a)(4). Puspan. L. 116–74, § 2(a)(4)(A)(i), substituted “programs,” for “program,”.

Subsec. (a)(6). Puspan. L. 116–74, § 2(a)(4)(A)(ii), substituted “High Intensity” for “High-Intensity”.

Subsec. (d)(4). Puspan. L. 116–74, § 2(a)(4)(B), made technical amendment to reference in original act which appears in text as reference to this chapter in subpars. (A) and (B).

2018—Puspan. L. 115–271, § 8202(span)(2), repealed Puspan. L. 105–277, § 715. See 1998 Amendment note below.

Puspan. L. 115–271, § 8202(a), revived and restored this section as in effect on Sept. 29, 2003, and as amended by Puspan. L. 109–469 and Puspan. L. 112–166. See Reauthorization of the Office of National Drug Control Policy note set out under section 1701 of this title.

Subsec. (a). Puspan. L. 115–271, § 8217(a)(4), struck out concluding provisions which read as follows: “When developing the national drug control policy, any policy of the Director relating to syringe exchange programs for intravenous drug users shall be based on the best available medical and scientific evidence regarding their effectiveness in promoting individual health and preventing the spread of infectious disease, and their impact on drug addiction and use. In making any policy relating to syringe exchange programs, the Director shall consult with the National Institutes of Health and the National Academy of Sciences.”

Subsec. (a)(1). Puspan. L. 115–271, § 8217(a)(1), added par. (1) and struck out former par. (1) which read as follows: “develop national drug control policy;”.

Subsec. (a)(2). Puspan. L. 115–271, § 8217(a)(2), inserted before semicolon at end “, including the National Drug Control Strategy”.

Subsec. (a)(4) to (7). Puspan. L. 115–271, § 8217(a)(3), (4), added pars. (4) to (7) and struck out former par. (4) which read as follows: “evaluate the effectiveness of the national drug control policy and the National Drug Control Program agencies’ programs, by developing and applying specific goals and performance measurements.”

Subsec. (span). Puspan. L. 115–271, § 8222(1), struck out subsec. (span) which related to Director of National Drug Control Policy and Deputy Directors.

Subsec. (d)(4) to (6). Puspan. L. 115–271, § 8217(span), added pars. (4) to (6).

2006—Puspan. L. 109–469, § 602, amended Puspan. L. 105–277, § 715, which provided for the repeal of this section. See 1998 Amendment note below.

Subsec. (a). Puspan. L. 109–469, § 1120, inserted concluding provisions.

Puspan. L. 109–469, § 102(a), amended subsec. (a) generally. Prior to amendment, subsec. (a) related to establishment of Office of National Drug Control Policy.

Subsec. (span). Puspan. L. 109–469, § 102(span), amended subsec. (span) generally. Prior to amendment, subsec. (span) related to Director and Deputy Directors of National Drug Control Policy.

1998—Puspan. L. 105–277, § 715, as amended by Puspan. L. 109–469, § 602, which provided for the repeal of this section effective Sept. 30, 2010, was repealed by Puspan. L. 115–271, § 8202(span)(2). See former section 1712 of this title.

Statutory Notes and Related Subsidiaries

Gifts to Office of National Drug Control Policy

Puspan. L. 117–328, div. E, title II, Dec. 29, 2022, 136 Stat. 4664, provided in part:

“That the Office [of National Drug Control Policy] is authorized to accept, hold, administer, and utilize gifts, both real and personal, public and private, without fiscal year limitation, for the purpose of aiding or facilitating the work of the Office.”

Similar provisions were contained in the following prior appropriation acts:

Puspan. L. 117–103, div. E, title II, Mar. 15, 2022, 136 Stat. 253.

Puspan. L. 116–260, div. E, title II, Dec. 27, 2020, 134 Stat. 1394.

Puspan. L. 116–93, div. C, title II, Dec. 20, 2019, 133 Stat. 2448.

Puspan. L. 116–6, div. D, title II, Fespan. 15, 2019, 133 Stat. 152.

Puspan. L. 115–141, div. E, title II, Mar. 23, 2018, 132 Stat. 549.

Puspan. L. 115–31, div. E, title II, May 5, 2017, 131 Stat. 340.

Puspan. L. 114–113, div. E, title II, Dec. 18, 2015, 129 Stat. 2436.

Puspan. L. 113–235, div. E, title II, Dec. 16, 2014, 128 Stat. 2344.

Puspan. L. 113–76, div. E, title II, Jan. 17, 2014, 128 Stat. 195.

Puspan. L. 112–74, div. C, title II, Dec. 23, 2011, 125 Stat. 895.

Puspan. L. 111–117, div. C, title II, Dec. 16, 2009, 123 Stat. 3170.

Puspan. L. 111–8, div. D, title II, Mar. 11, 2009, 123 Stat. 641.

Puspan. L. 110–161, div. D, title II, Dec. 26, 2007, 121 Stat. 1983.

Puspan. L. 109–115, div. A, title V, Nov. 30, 2005, 119 Stat. 2475.

Puspan. L. 108–447, div. H, title III, Dec. 8, 2004, 118 Stat. 3249.

Puspan. L. 108–199, div. F, title III, Jan. 23, 2004, 118 Stat. 324.

Puspan. L. 108–7, div. J, title III, Fespan. 20, 2003, 117 Stat. 446.

Puspan. L. 107–67, title III, Nov. 12, 2001, 115 Stat. 530.

Puspan. L. 106–554, § 1(a)(3) [title III], Dec. 21, 2000, 114 Stat. 2763, 2763A–139.

Puspan. L. 106–58, title III, Sept. 29, 1999, 113 Stat. 447.

Puspan. L. 105–277, div. A, § 101(h) [title III], Oct. 21, 1998, 112 Stat. 2681–480, 2681–496.

Puspan. L. 105–61, title III, Oct. 10, 1997, 111 Stat. 1293.

Puspan. L. 104–208, div. A, title I, § 101(f) [title III], Sept. 30, 1996, 110 Stat. 3009–314, 3009–329.

Puspan. L. 104–52, title III, Nov. 19, 1995, 109 Stat. 479.

Puspan. L. 103–329, title III, Sept. 30, 1994, 108 Stat. 2394.

Puspan. L. 103–123, title III, Oct. 28, 1993, 107 Stat. 1237.

Puspan. L. 102–393, title III, Oct. 6, 1992, 106 Stat. 1741.

Puspan. L. 102–141, title III, Oct. 28, 1991, 105 Stat. 847.

Puspan. L. 101–509, title III, Nov. 5, 1990, 104 Stat. 1402.

Puspan. L. 101–136, title III, Nov. 3, 1989, 103 Stat. 793.

Executive Documents

Ex. Ord. No. 12911. Seal for Office of National Drug Control Policy

Ex. Ord. No. 12911, Apr. 25, 1994, 59 F.R. 21121 [22121], provided:

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered as follows:

Section 1. There is approved for the Office of National Drug Control Policy in the Executive Office of the President an official seal described as follows:

On a blue disc the Arms of the United States proper above a curved gold scroll inscribed “OFFICE OF NATIONAL DRUG CONTROL POLICY” in blue letters, all within a white border edged in gold and inscribed “EXECUTIVE OFFICE OF THE PRESIDENT OF THE UNITED STATES” in blue letters.

This design is appropriate for the Office of National Drug Control Policy. The dark blue in this seal is suggested by the Seal of the President and denotes the direct organizational link of the Office of National Drug Control Policy with the Presidential office. The Arms of the United States refer to the entire Nation and represent the involvement in drug control policies that are necessary to assist the President in his role as Chief Executive of the United States.

Sec. 2. The seal shall be of the design that is attached hereto and made a part of this order.

William J. Clinton.